non injection glp 1 How GLP-1 medications are transforming diabetes and weight loss treatment The GLP-1 Agonists and Obesity:

Available from: 51

Unlike GLP-1, GIP has not been found to possess a similar neural signaling mechanism for decelerating gastric emptying (54, 162)

For once-weekly injections, some patients prefer administering the dose on a day when they can rest if needed

In a 48-week phase II clinical trial conducted on patients with type 2 diabetes and obesity, treatment with a dose of 10 mg/kg of bimagrumab resulted in a significant reduction in fat mass by 20.5% (compared to 0.5% in the placebo group), while lean body mass increased by 3.6% (as opposed to a decrease of 0.8% in the placebo group), leading to an overall body weight reduction of -6.5%, which was substantially better than the -0.8% observed in the placebo group